Table of Contents
NSI 189 is a neurogenic compound that is being studied for its potential as an antidepressant. The current research of the drug claims it could be a possible treatment for individuals who do not respond well to conventional antidepressant medications. The compound has gone through phase I and II clinical trials for its antidepressant properties, but the phase II trial failed to meet effectiveness outcomes. It is currently still being studied as a possible treatment for other conditions.
Medical History
NSI 189 is being researched by the biotechnology company Neuralstem, Inc. The company has stated that it is not only investigating the compound for use as a treatment of major depressive disorders, it is also undergoing trials for use as a treatment for Alzheimer’s disease, stroke, post-traumatic stress disorder, diabetic neuropathy, as well as cognitive impairment and decline.
Research of the neurogenic compound suggests that it works by stimulating the growth of new brain cells and nerve cells through a process called neurogenesis. The neurogenesis appears to affect the hippocampus primarily, which is responsible for learning, memory, and emotion. Scientists believe the compound has the potential to treat various neurological and nerve conditions.
NSI-189 Phosphate Powder – 1g
Benefits
The study NSI 189 has uncovered several potential benefits it exudes on the brain. While more research is required to prove the benefits and safety of the compound, the current clinical trials show promise. Some of the potential benefits of the compound include:
- Improvement of symptoms of depression
- Improved moodImproved memory
- Enhanced executive function
- Lessening the effects of a stroke if given within six hours
- Protect and stimulate the growth of nerves
- A reduction and easement of symptoms of Angelman Syndrome
- Improvement of neuropathy pain and symptoms
- Improved memory recall
- Improved emotional responses
- Increased articulationEnhanced clarity of thoughts
- Increased mental focus
Side Effects
NSI 189 is not approved by the FDA, and there is not enough scientific information available to verify its safety. To lessen any potential side effects, it is advisable to only take the lowest possible dose of the compound at first in order to judge how it will affect the body. The possible side effects of this compound include nausea, fatigue, heart palpitations, headache, increased anxiety, visual perception changes, loss of memory, dissociation, decreased appetite, increased heart rate, delirium, and a drop in blood sugar.
As there have been no long term studies for this compound, the long term effects and overall safety are unknown. For this reason, it is not suggested to take the compound if an individual is pregnant or breastfeeding. It is also not advisable to take the compound if an individual is taking a prescription medication for the treatment of depression, neuropathy, or if they have low blood sugar.
Dosage
As of yet, a recommended dosage does not exist for NSI 189, as there have not been enough clinical trials with associated research to find a viable standard dose. As with any unproven supplement, it is recommended to consult a healthcare provider before deciding to take the substance. The healthcare provider may be able to provide more information on the compound and give the correct dosage for the individual.
NSI-189 Phosphate Powder – 1g
The information available on the best dosage is from the completed clinical trials and personal reviews of the compound. The noted dosages are between 40 mg a day up to 100 mg a day. It is advised to begin with the lowest dosage and work up from there if needed. But many personal reviewers felt the effects after a single dose with the lowest recommended dosage.
Overall, NSI 189 is an investigational compound being studied for its antidepressant properties as well as for its potential as a treatment for other neurological conditions. While the current research notes it as a relatively safe drug, there are a host of possible side effects that have been experienced both by those in the clinical trials and individuals who have used the drug as a supplement.